Soil acidity and mobile aluminum status in pseudogley soils in the Čačak-Kraljevo Basin

Soil acidity and aluminum toxicity are considered the most damaging soil conditions affecting the growth of most crops. This paper reviews the results of tests of pH, exchangeable acidity and the mobile aluminum (Al) concentration in profiles of pseudogley soils from the Čačak-Kraljevo Basin. For these purposes, 102 soil pits were dug in 2009 in several sites around the Čačak-Kraljevo Basin. The tests encompassed 54 field, 28 meadow, and 20 forest soil samples. Samples of soil in a disturbed state were taken from the Ah and Eg horizons (102 samples), from the B1tg horizon in 39 field, 24 meadow and 15 forest pits (a total of 78 samples) and from the B2tg horizon in 14 field, 11 meadow, and 4 forest pits (a total of 29 samples). The mean pH values (1 M KCl) of the tested soil profiles were 4.28, 3.90 and 3.80 for the Ah, Eg and B1tg horizons, respectively. The soil pH of the forest samples was lower than those in the meadow and arable land samples (mean values of 4.06, 3.97 and 3.85 for arable land, meadow and forest samples, respectively). The soil acidification was especially intensive in the deep horizons; thus, 27 (Ah), 77 (Eg) and 87 % (B1tg) of the soil samples had a pH value below 4.0. The mean values of the total exchangeable acidity (TEA) were 1.55, 2.33 and 3.40 meq (100 g)-1 for the Ah, Eg and B1tg horizons, respectively. The TEA values in the forest soils were considerably higher (3.39 meq (100 g)-1) than those in the arable and meadow soils (1.96 and 1.93 meq (100 g)-1, respectively). The mean mobile Al contents of the tested soil samples were 11.02, 19.58 and 28.33 mg Al (100 g)-1 for the Ah, Eg and B1tg horizons, respectively. According to the pH and TEA values, mobile Al was considerably higher in the forest soils (a mean value of 26.08 mg Al (100 g)-1) than in the arable and meadow soils (mean values of 16.85 and 16.00 mg Al (100 g) -1, respectively). The Eg and B1tg horizons of the forest soil had especially high mobile Al contents (mean values of 28.50 and 32.95 mg Al (100 g)-1, respectively). High levels of mobile Al were especially frequent in the forest soils, with 35 (Ah), 85.0 (Eg) and 93.3 % (B 1tg) of the tested samples ranging above 10 mg Al (100 g) -1

Kalcizacija kiselih zemljišta u centralnoj Srbiji

Acidic soils are preset over 60% of the total arable land in Central Serbia. Yields of the majority of field crops that are achieve on acid soils are low and poor quality. The introduction of control of soil fertility and application of amelioration measures, especially liming, are significantly influenced to improvement of fertility of acid soils and increase yields of cultivated plant species. Also, by neutralizing the acidity of the soil there were positive changes in the degree of weed infestation of crops, changes in the structure of weeds, as well as greater efficiency of protection of cultivated plants from weeds. A substantial portion of acid soils in Central Serbia is not under control of soil fertility and use of fertilizer and without implementation liming as a measure of amelioration. Also, in this area do not exist demonstration experiments in order to monitor changes that cause the application of liming in soils, as well as the promotion of this important amelioration measures.U radu je dat pregled najvažnijih rezultata neutralizacije kiselih zemljišta Centralne Srbije primenom pH melioranata, naročiro upotrebom krečnog đubriva "Njival Ca". Na osnovu dosadašnjih istraživanja utvrđen je veoma pozitivan efekat primene kalcizacije na podizanje nivoa plodnosti svih proučavanih tipova kiselih zemljišta i to preko: povećanja njihove pH vrednosti, sadržaja organske materije, ukupnog azota, lakopristupačnog fosfora i kalijuma, značajnog smanjenja sadržaja mobilnog aluminijuma, gvožđa i mangana, kao i sadržaja pristupačnih formi teških metala. Takođe, neutralizacijom kiselih zemljišta značajno su povećani prinosi gajenih biljnih vrsta (od 30% do nekoliko puta), naročito osetljivih na niske pH vrednosti i sadržaj mobilnog Al. Primenom ove pedomeliorativne mere na kiselim zemljištima utvrđeno je i smanjenje zakorovljenosti i pozitivne promene florističkog sastava korova u usevima pojedinih biljnih vrsta

FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function

Diabetes in pregnancy is associated with adverse pregnancy outcomes including preterm birth. Although the mechanisms leading to these pregnancy complications are still poorly understood, aberrant angiogenesis and endothelial dysfunction play a key role. FKBPL and SIRT-1 are critical regulators of angiogenesis, however, their roles in pregnancies affected by diabetes have not been examined before in detail. Hence, this study aimed to investigate the role of FKBPL and SIRT-1 in pre-gestational (type 1 diabetes mellitus, T1D) and gestational diabetes mellitus (GDM). Placental protein expression of important angiogenesis proteins, FKBPL, SIRT-1, PlGF and VEGF-R1, was determined from pregnant women with GDM or T1D, and in the first trimester trophoblast cells exposed to high glucose (25 mM) and varying oxygen concentrations [21%, 6.5%, 2.5% (ACH-3Ps)]. Endothelial cell function was assessed in high glucose conditions (30 mM) and following FKBPL overexpression. Placental FKBPL protein expression was downregulated in T1D (FKBPL; p<0.05) whereas PlGF/VEGF-R1 were upregulated (p<0.05); correlations adjusted for gestational age were also significant. In the presence of GDM, only SIRT-1 was significantly downregulated (p<0.05) even when adjusted for gestational age (r=-0.92, p=0.001). Both FKBPL and SIRT-1 protein expression was reduced in ACH-3P cells in high glucose conditions associated with 6.5%/2.5% oxygen concentrations compared to experimental normoxia (21%; p<0.05). FKBPL overexpression in endothelial cells (HUVECs) exacerbated reduction in tubule formation compared to empty vector control, in high glucose conditions (junctions; p<0.01, branches; p<0.05). In conclusion, FKBPL and/or SIRT-1 downregulation in response to diabetic pregnancies may have a key role in the development of vascular dysfunction and associated complications affected by impaired placental angiogenesis

Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.

ContextPreeclampsia is a leading cardiovascular complication in pregnancy lacking effective diagnostic and treatment strategies.ObjectiveTo investigate the diagnostic and therapeutic target potential of the angiogenesis proteins, FK506-binding protein like (FKBPL) and CD44.Design and interventionFKBPL and CD44 plasma concentration or placental expression were determined in women pre- or postdiagnosis of preeclampsia. Trophoblast and endothelial cell function was assessed following mesenchymal stem cell (MSC) treatment and in the context of FKBPL signaling.Settings and participantsHuman samples prediagnosis (15 and 20 weeks of gestation; n ≥ 57), or postdiagnosis (n = 18 for plasma; n = 4 for placenta) of preeclampsia were used to determine FKBPL and CD44 levels, compared to healthy controls. Trophoblast or endothelial cells were exposed to low/high oxygen, and treated with MSC-conditioned media (MSC-CM) or a FKBPL overexpression plasmid.Main outcome measuresPreeclampsia risk stratification and diagnostic potential of FKBPL and CD44 were investigated. MSC treatment effects and FKBPL-CD44 signaling in trophoblast and endothelial cells were assessed.ResultsThe CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of preeclampsia. At 20 weeks of gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.3-fold increased risk of preeclampsia (odds ratio = 2.3, 95% confidence interval [CI] 1.03-5.23, P = 0.04). In combination with high mean arterial blood pressure (>82.5 mmHg), the risk further increased to 3.9-fold (95% CI 1.30-11.84, P = 0.016). Both hypoxia and MSC-based therapy inhibited FKBPL-CD44 signaling, enhancing cell angiogenesis.ConclusionsThe FKBPL-CD44 pathway appears to have a central role in the pathogenesis of preeclampsia, showing promising utilities for early diagnostic and therapeutic purposes

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

BACKGROUND Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. METHODS In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. FINDINGS Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). INTERPRETATION Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes. FUNDING Intercept Pharmaceuticals

Performance of blue lupin (Lupinus angustifolius L.) cultivars on a pseudogley soil in Serbia

The goal of modern blue lupin (Lupinus angustifolius L.) breeding programs, such as the one that is carried out in the Saatzucht Steinach GmbH in Bornhof, Germany, is the improvement of tolerance to abiotic and biotic stress and certain morphological and physiological changes. Blue lupin is almost unknown in Serbia, but a recently launched breeding program on white (Lupinus albus L.) and blue lupins in the Institute of Field and Vegetable Crops in Novi Sad provided encouraging results on the introduction of these two species in the country. A small-plot trial was carried out on a pseudogley soil, with a pH value of 4.79, at the Experiment Field of the Dr Dorde Radic Secondary School of Agriculture in Kraljevo during 2006 and 2007. In comparison with all other cultivars, the cultivar Bolivio produced higher grain yield (2311 kg ha¹), while the lowest grain yield was in the cultivar Boregine (1525 kg ha⁻¹). The annual grain yield in these six examined blue lupin cultivars ranged from 1425 kg ha⁻¹, in the cultivar Boruta in 2006, to, 3005 kg ha⁻¹, in the cultivar Bolivio in 2006

Impact of long-term fertilization on yield in wheat grown on soil type vertisol

© 2020, University of Montenegro. All rights reserved. Experiments were carried out at stationary in Kragujevac, in Serbia, during the three growing seasons. The primary aim of the research was perceiving of the influence of long-term usage of the same amounts and rates of nitrogen, phosphorus and potassium on the yield and grain quality of winter wheat variety „Kruna“. Uptake NPK uptake by wheat ranged from 120 kg ha-1 nitrogen, from 60 to 100 kg ha-1 phosphorus and 60 kg ha-1 potassium, respectively, depending on treatments type. The grain yield of the wheat was significantly lower in control (treatment without fertilizer). The three-year grain yield of winter wheat was the highest in the NP1K and NP2K (4.367 and 4.531 t ha-1) treatments. In terms of investigated traits, particularly grain yield and test weight fertilizer expressed more efficiency in the 2014/2015. Variance analysis showed statistically very significant differences for grain yield, 1.000-grain weight and test weight between the vegetation seasons and very significant differences for grain yield and 1000-grain weight between the variants of fertilization. Variance analysis showed very significant differences for 1000-grain weight between the interaction of the vegetation seasons and variants of fertilization. It could be concluded that the grain yield in all treatments in the 2014/2015 growing season was significantly greater than in the other examined years, mostly as the result of highly favorable weather conditions at major stages of plant development wheat